In this video, Behfar Ehdaie, MD, MPH, compared magnetic resonance (MR)–guided focused ultrasound (MRgFUS) with other forms of focal therapy used to treat prostate cancer as well as the learning curve associated with this specific therapy.
During the 2021 AUA Annual Meeting, Ehdaie presented a study showing that in some men with intermediate-risk prostate cancer, MRgFUS focal therapy may be an effective alternative to radical therapy that improves quality-of-life measures such as sexual function and urinary incontinence.
Ehdaie is an assistant member of the urology service department of surgery at Memorial Sloan Kettering Cancer Center, New York City, New York.
Plant-based diets linked to lower risk of prostate cancer progression and recurrence
March 7th 2023"These findings may directly inform clinical care, such as providing diet recommendations for managing health, and potentially offer other positive health benefits for preventing numerous chronic diseases,” said Bradley Alexander McGregor, MD.
Gene therapy EG-70 shows early promise in BCG-unresponsive NMIBC
February 27th 2023"While the data are still early, EG-70's safety profile and efficacy are well on their way towards establishing a new benchmark for monotherapy treatment of high-risk NMIBC with BCG-unresponsive carcinoma in situ,” said lead study author Gary Steinberg MD.
Real-world study investigates first-line avelumab maintenance for metastatic urothelial carcinoma
February 20th 2023Baseline findings showed that patients treated with first-line platinum-based chemotherapy prior to avelumab maintenance experienced a complete response rate of 13% and a partial response rate of 68% to chemotherapy.
2 Clarke Drive
Cranbury, NJ 08512